Quantcast

Latest Liraglutide Stories

2014-10-08 23:01:34

The Firm is evaluating Byetta lawsuits and other legal claims that allege the use of diabetes drugs called incretin mimetics caused patients to develop pancreatic cancer, pancreatitis or thyroid cancer. New York, New York (PRWEB) October 08, 2014 The federal judge overseeing dozens of Byetta lawsuits (http://www.byettalawsuit.com ) and other product liability claims involving incretin mimetic diabetes drugs has denied a request by plaintiffs’ to compel defendants to produce source...

2014-09-24 23:02:01

The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer. New York, New York (PRWEB) September 24, 2014 Byetta lawsuits(http://www.byettalawsuit.com) and other product liability claims that allege incretin mimetic Type 2 diabetes medications caused patients to develop pancreatic cancer continue to move forward in U.S. courts, Bernstein Liebhard LLP...

2014-09-17 12:27:46

SGLT-2 Inhibitors Will Be the Fastest-Growing Drug Class Over the 2013-2023 Forecast Period, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that as physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes therapies continue to experience increased use despite attempts by payer and reimbursement authorities to limit use of these more expensive drugs. As the robust...

2014-09-11 23:01:20

The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2 diabetes drug. New York (PRWEB) September 11, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, including Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-09-11 20:21:50

WASHINGTON, Sept. 11, 2014 /PRNewswire/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda(®), the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity. Based on the data contained in the NDA for Saxenda(®), the FDA asked the panel members to discuss whether...

2014-08-30 23:02:07

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New York, New York (PRWEB) August 30, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a statement issued by AstraZeneca PLC on July 31, 2014, Byetta and Bydureon (an extended-release...

2014-08-10 23:01:12

The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid cancer. New York, New York (PRWEB) August 10, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, such as Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-07-17 04:21:04

MT Services LLC informs plaintiffs on various pharmaceutical drug cases available to obtain lawsuit funding and legal assistance BRONX, N.Y., July 17, 2014 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products:...

2014-07-07 12:28:53

Agents That Can Elicit Greater Weight Loss Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group BURLINGTON, Mass., July 7, 2014 /PRNewswire/ -- Decision Resources Group finds that Novo Nordisk's fixed-dose combination (FDC) therapy insulin degludec/liraglutide (Xultophy, formerly known as IDegLira) is set to become the clinical gold-standard among FDCs used to treat patients with type 2 diabetes. The competitive advantages that this...

2014-07-05 23:01:25

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication. New York, NY (PRWEB) July 05, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related